162 related articles for article (PubMed ID: 32754904)
1. Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
Derrieux C; Gish A; Caulier A; Grardel N; Garidi R; Joris M; Assouan D; Poulain S; Decool G; Ferret Y; Caillault-Venet A; Marolleau JP; Preudhomme C; Boyer T
Br J Haematol; 2020 Nov; 191(3):506-509. PubMed ID: 32754904
[No Abstract] [Full Text] [Related]
2. Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
Zur Stadt U; Alawi M; Adao M; Indenbirken D; Escherich G; Horstmann MA
Blood Cancer J; 2019 Nov; 9(12):96. PubMed ID: 31784504
[TBL] [Abstract][Full Text] [Related]
3. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
4. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis.
Csinady E; van der Velden VH; Joas R; Fischer S; de Vries JF; Beverloo HB; König M; Pötschger U; van Dongen JJ; Mann G; Haas OA; Panzer-Grümayer ER
Leukemia; 2009 May; 23(5):870-6. PubMed ID: 19148138
[TBL] [Abstract][Full Text] [Related]
6. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection.
Li AH; Rosenquist R; Forestier E; Lindh J; Roos G
Leuk Res; 2001 Dec; 25(12):1033-45. PubMed ID: 11684274
[TBL] [Abstract][Full Text] [Related]
7. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
[TBL] [Abstract][Full Text] [Related]
8. Multiplex PCR reaction for the detection and identification of immunoglobulin kappa deleting element rearrangements in B-lineage leukaemias.
Stolz F; Panzer S; Panzer-Grümayer ER
Br J Haematol; 1999 Aug; 106(2):486-90. PubMed ID: 10460610
[TBL] [Abstract][Full Text] [Related]
9. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
[TBL] [Abstract][Full Text] [Related]
10. Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications.
Darzentas F; Szczepanowski M; Kotrová M; Hartmann A; Beder T; Gökbuget N; Schwartz S; Bastian L; Baldus CD; Pál K; Darzentas N; Brüggemann M
Front Immunol; 2023; 14():1125017. PubMed ID: 37143651
[TBL] [Abstract][Full Text] [Related]
11. Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia.
Rosenquist R; Thunberg U; Li AH; Forestier E; Lönnerholm G; Lindh J; Sundström C; Sällström J; Holmberg D; Roos G
Eur J Haematol; 1999 Sep; 63(3):171-9. PubMed ID: 10485272
[TBL] [Abstract][Full Text] [Related]
12. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
13. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
14. Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-kappa and heavy-chain gene rearrangements.
Sutton R; Bahar AY; Kwan E; Giles JE; Venn NC; Tran S; Hackenberg N; Pozza LD; Marshall GM; Haber M; van der Velden VH; Norris MD
Leukemia; 2008 Dec; 22(12):2265-7. PubMed ID: 18496559
[No Abstract] [Full Text] [Related]
15. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC; Zhang B; Narasimhan B; Carlton V; Zheng J; Moorhead M; Krampf MR; Jones CD; Waqar AN; Faham M; Zehnder JL; Miklos DB
Leukemia; 2013 Aug; 27(8):1659-65. PubMed ID: 23419792
[TBL] [Abstract][Full Text] [Related]
16. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq.
Li Z; Jiang N; Lim EH; Chin WHN; Lu Y; Chiew KH; Kham SKY; Yang W; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Leukemia; 2020 Sep; 34(9):2418-2429. PubMed ID: 32099036
[TBL] [Abstract][Full Text] [Related]
17. A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
Derrieux C; Freynet N; Frayfer J; Delabesse E; Clappier E; Defasque S; Broutier H; Fouillard L
Leuk Lymphoma; 2018 Oct; 59(10):2489-2492. PubMed ID: 29424254
[No Abstract] [Full Text] [Related]
18. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.
Herold T; Schneider S; Metzeler KH; Neumann M; Hartmann L; Roberts KG; Konstandin NP; Greif PA; Bräundl K; Ksienzyk B; Huk N; Schneider I; Zellmeier E; Jurinovic V; Mansmann U; Hiddemann W; Mullighan CG; Bohlander SK; Spiekermann K; Hoelzer D; Brüggemann M; Baldus CD; Dreyling M; Gökbuget N
Haematologica; 2017 Jan; 102(1):130-138. PubMed ID: 27561722
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
20. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
